Results 71 to 80 of about 30,368 (178)

Assessment of Antimicrobial Resistance in M. leprae Strains From Kiribati

open access: yesTropical Medicine &International Health, Volume 31, Issue 8, Page 1035-1042, August 2026.
ABSTRACT Objectives Kiribati has one of the highest rates of leprosy worldwide. A nationwide screening and chemoprophylaxis program for household leprosy contacts was introduced in 2018. In 2022, population‐wide screening and rifamycin‐based treatment or chemoprophylaxis for leprosy and tuberculosis was introduced as part of the PEARL and COMBINE ...
Patrick O. Campbell   +10 more
wiley   +1 more source

Clarithromycin adjunct treatment leads to substantial financial savings in community-acquired pneumonia: sub-analysis of the ACCESS trial

open access: yesJournal of Global Antimicrobial Resistance
BACKGROUND: In the ACCESS randomized controlled trial addition of oral clarithromycin 500mg two times daily for seven days to standard-of-care (SoC) antibiotics provided substantial clinical benefit in adult patients hospitalized for community-acquired ...
Vasiliki Rapti   +7 more
doaj   +1 more source

Clarithromycin sustained-release tablet may be an improper therapy for the eradication of

open access: yesTherapeutic Advances in Gastroenterology
Background: Clarithromycin plays an important role in eradicating Helicobacter pylori ( H. pylori ) through quadruple therapy. However, there is limited research on whether different forms of clarithromycin dosage have similar efficacies against H ...
Xingsheng Zuo   +4 more
doaj   +1 more source

Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Prospective Randomized Comparison of 7- and 14-Day Treatment Regimens

open access: yesGut and Liver
Background/Aims: Bismuth-based quadruple therapy (BQT) is a treatment option for clarithromycin-resistant Helicobacter pylori (HP) infection. The aim of this study was to compare the efficacy of 7-day BQT with that of 14-day BQT as first-line treatment ...
Chul-Hyun Lim, Jung-Hwan Oh
doaj   +1 more source

Exploring the Molecular Mechanisms of Macrolide Resistance in Laboratory Mutant Helicobacter pylori

open access: yesAntibiotics
Resistance to clarithromycin, a macrolide antibiotic used in the first-line treatment of Helicobacter pylori infection, is the most important cause of treatment failure. Although most cases of clarithromycin resistance in H.
Meltem Ayaş   +4 more
doaj   +1 more source

Detection of Helicobacter pylori and the Genotypes of Resistance to Clarithromycin, Fluoroquinolones, and Metronidazole in Gastric Biopsies: An In Silico Analysis to Help Understand Antibiotic Resistance

open access: yesCurrent Issues in Molecular Biology
Antibiotic resistance in Helicobacter pylori is increasing rapidly and emerging as a major factor in treatment failure. We aimed to identify genetic mutations associated with resistance to clarithromycin (23S rRNA peptidyl transferase), fluoroquinolones (
Pedro Valada   +5 more
doaj   +1 more source

Clinical Observation on Different Triple Regimens Therapy for Eradication of Helicobacter Pylori Infection

open access: yesHuli yanjiu, 2003
Objective: to observe the eradication efficacy of different triple regimens of either rabeprazole, clarithromycin plus amoxycillin or omeprazole, clarithromycin plus amoxycillin on curing patients with helicobacter pylori (Hp) infection, Hp related ...
霍丽娟
doaj  

In vitro activity and pharmacodynamic/pharmacokinetic parameters of clarithromycin and azithromycin: why they matter in the treatment of respiratory tract infections

open access: yesInfection and Drug Resistance, 2019
Ross J Davidson1–4 1Department of Pathology and Laboratory Medicine, Division of Microbiology, Queen Elizabeth II Health Sciences Center, Halifax, NS, Canada; 2Department of Medicine, 3Department of Pathology, 4Department of Microbiology & ...
Davidson RJ
doaj  

Clarithromycin for Children

open access: yesCanadian Journal of Infectious Diseases and Medical Microbiology, 1995
openaire   +3 more sources

Home - About - Disclaimer - Privacy